Vifor Pharma to propose Dr Alexandre LeBeaut as Board member
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
ST. GALLEN, Switzerland -- Businesswire -- Regulatory News:
Vifor Pharma today announced that the Board of Directors will propose Dr Alexandre LeBeaut for election to the Board at the next Annual General Meeting on 6 May 2021.
Jacques Theurillat, Chairman of Vifor Pharma, commented: “We are very pleased to nominate Alexandre LeBeaut for election to the Vifor Pharma Group Board of Directors. Dr LeBeaut has broad experience in R&D, clinical development and research/medical affairs. He will optimally complement the Board to assess Vifor Pharma’s pipeline development and clinical programs aiming to become the global leader in iron deficiency, nephrology and cardio-renal therapies.”
Alexandre LeBeaut was formerly Chief Scientific Officer and Executive Vice-President R&D at Ipsen Bioscience Inc. with more than 25 years of extensive global R&D experience in the biopharmaceutical industry including Schering-Plough, Novartis, Sanofi, Axcan Pharmaceuticals and Bluebird Bio. Alexandre is a French and US citizen and a pediatrician who holds a M.D. from Paris University. He is a member of the Board of Calypso Biotech.
After 25 years with Vifor Pharma and four years of service on the Board of Directors, Dr Gianni Zampieri has decided that he will not stand for re-election to the Board at the Annual General Meeting in 2021. “With his expertise and valuable insights, Gianni Zampieri has been instrumental in the strategic development of the company in various roles. Because of his profound strategic foresight he drove the development and the launch of Ferinject, which is now a blockbuster product for the company.” As CEO for Vifor Pharma he successfully managed the separation of the group and the IPO of Galenica. Gilbert Achermann has also decided to step down from the Board of Vifor Pharma and therefore does not stand for re-election. “On behalf of the Board of Directors, I extend our sincere gratitude to both Directors for their excellent and successful work for Vifor Pharma, and we wish them all the best for their private and professional future” said Jacques Theurillat.
Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is a partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma and Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care). Vifor Pharma Group is headquartered in Switzerland, and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348).
For more information, please visit viforpharma.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210201005792/en/
이 뉴스는 기업·기관·단체가 뉴스와이어를 통해 배포한 보도자료입니다.
출처:Vifor Pharma Group
보도자료 통신사 뉴스와이어(www.newswire.co.kr) 배포
Copyright © 뉴스와이어. 무단전재 및 재배포 금지.
- 삼성전자, 갤럭시 S24 등 기존 모델에 최신 ‘갤럭시 AI’ 업데이트 실시 - 뉴스와이어
- 제주 에코랜드, 한가위 특집이벤트 ‘민속한마당’ 개최 - 뉴스와이어
- LG에너지솔루션 사내독립기업 AVEL, 국내 최초 배전망 연계형 ESS 발전소 완공 - 뉴스와이어
- 삼성전자, IFA 2024에서 뮤직 프레임 ‘위키드’ 에디션 공개 - 뉴스와이어
- 전기차 화재, 빠른 감지와 신고가 무엇보다 중요… 화재 감지 AI 카메라 ME100 출시 - 뉴스와이어
- 지뉴소프트 ‘산업 적용 위한 초분광 영상분석 기술 개발’ 국책 과제 수주 - 뉴스와이어
- 예술과 일상이 만나는 야외 문화축제 ‘아트 인 시리즈’ - 뉴스와이어
- 청소년들의 사회적 기업 와가카, 국제청소년창업대회 ‘2024 쎄이지월드컵’ 월드 챔피언 쾌거 -
- 오타니 쇼헤이, 비츠 브랜드의 새 앰버서더로 출격 - 뉴스와이어
- KG 모빌리티, 전기차 스마트 충전기 대응 소프트웨어 개발 완료 - 뉴스와이어